You just read:

DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

News provided by

DNAtrix, Inc.

Nov 24, 2019, 12:00 ET